Last reviewed · How we verify
NCT06563700
Novel Lenses for Myopia Progression Trial
NA trial testing spectacle lens in Myopia, Progressive in 300 participants. Participants enrolled and being followed up; not accepting new ones.
31 July 2027
Quick facts
| Lead sponsor | Shanghai Eye Disease Prevention and Treatment Center |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 300 |
| Start date | 16 August 2024 |
| Primary completion | 31 July 2027 |
| Estimated completion | 31 July 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- spectacle lens
- single vision lens
Conditions studied
- Myopia, Progressive — all drugs for Myopia, Progressive →
Sponsor
Shanghai Eye Disease Prevention and Treatment Center — full company profile →
Who can join
Adults 7 to 13, any sex, with Myopia, Progressive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-center , prospective, randomised, longitudinal study to evaluate rate of myopia progression with novel lenses compared to Single-Vision spectacles. A total of 342 children will be recruited where 57 participants each are randomised to wear one of 5 test spectacle lens designs or a single vision lens (control) for 12 months. At the end of 12 months, those randomised to single vision lenses will be transferred to one of the test lenses and all the groups continued for another 12 months. Myopia progression during the second year with test lenses will be compared to historical or published controls.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06563700
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myopia, Progressive
Currently open trials in the same condition.
- NCT06927388 — Myopia Progression With Freeform Myopia Control Spectacles · NA · active not recruiting
- NCT07055815 — Impact of Digital Screen Time in Progression of Myopia in Children · active not recruiting
- NCT06389110 — Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elo · Phase 3 · recruiting
- NCT06647160 — Safety and Efficacy of Blue Star MAX-5 Lenses in Myopia Control · NA · active not recruiting
- NCT06520124 — Stellest Lens Wear in Adult Progressing Myopes · NA · active not recruiting
Other Shanghai Eye Disease Prevention and Treatment Center trials
Trials by the same sponsor.
- NCT07535658 — Efficacy of Multi-Type Photolithography Flat Microstructure Lenses for Childhood Myopia Control · NA · not yet recruiting
- NCT07514039 — Photolithography Microstructure Myopia Management Lenses in Preventing and Controlling Myopia in Children and Adolescent · NA · enrolling by invitation
- NCT07312214 — LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia · NA · recruiting
- NCT07284147 — 3D Designed Defocus Lenses on Myopia Control in Children and Adolescents · NA · enrolling by invitation
- NCT07120737 — Efficacy and Safety of Spectacle Lenses With H.A.L.T. MAX Technology on High Myopia Control in Children and Adolescents · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06563700 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Eye Disease Prevention and Treatment Center
- Last refreshed: 3 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06563700.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing